Azzad Asset Management Inc /Adv Intellia Therapeutics, Inc. Transaction History

Azzad Asset Management Inc /Adv

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	BUY	$23.82 - $32.8 $4,120 - $5,674	173 Added 2.08%	8,496 $234 Million
Q4 2023 Apr 01, 2024	BUY	$23.16 - $32.34 $13,224 - $18,466	571 Added 7.37%	8,323 $254 Million
Q3 2023 Apr 01, 2024	BUY	$31.62 - $45.78 $47,082 - $68,166	1,489 Added 23.77%	7,752 $245 Million
Q2 2023 Apr 01, 2024	BUY	$34.58 - $46.03 $15,699 - $20,897	454 Added 7.82%	6,263 $255 Million
Q1 2023 Apr 01, 2024	SELL	$33.3 - $44.82 $4,895 - $6,588	-147 Reduced 2.47%	5,809 $217 Million
Q4 2022 Apr 01, 2024	BUY	$33.21 - $62.69 $2,889 - $5,454	87 Added 1.48%	5,956 $208 Million
Q3 2022 Apr 01, 2024	SELL	$53.92 - $71.7 $10,891 - $14,483	-202 Reduced 3.33%	5,869 $328 Million
Q2 2022 Apr 01, 2024	BUY	$38.49 - $76.21 $22,709 - $44,963	590 Added 10.76%	6,071 $314 Million
Q1 2022 Apr 01, 2024	SELL	$58.27 - $118.99 $36,360 - $74,249	-624 Reduced 10.22%	5,481 $398 Million
Q4 2021 Apr 01, 2024	BUY	$100.76 - $138.36 $15,114 - $20,754	150 Added 2.52%	6,105 $722 Million
Q3 2021 Apr 01, 2024	SELL	$132.37 - $176.78 $129,854 - $173,421	-981 Reduced 14.14%	5,955 $799 Million
Q2 2021 Apr 01, 2024	BUY	$60.88 - $161.91 $12,784 - $34,001	210 Added 3.12%	6,936 $1.12 Billion
Q1 2021 Apr 01, 2024	BUY	$46.59 - $83.68 $313,364 - $562,831	6,726 New	6,726 $540 Million

326

88.8M

673K

865K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.59B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.